SCHEMBL4255064

SCHEMBL4255064

CCOC(=O)N1CCC(OC(c2ccccc2)c2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.59
CHRM2 P08172 1/20 0.58
HTR1A P08908 1/20 0.58
ADRA2A P08913 1/20 0.58
CYP2D6 P10635 1/20 0.58
CHRM1 P11229 1/20 0.58
DRD1 P21728 1/20 0.58
SLC6A2 P23975 1/20 0.58
ADRA1A P35348 1/20 0.58
OPRM1 P35372 1/20 0.58
DRD3 P35462 1/20 0.58
SLC6A3 Q01959 1/20 0.58
KCNH2 Q12809 1/20 0.58
HRH3 Q9Y5N1 1/20 0.58
GAA P10253 1/20 0.58
MAPK1 P28482 1/20 0.57
MGLL Q99685 1/20 0.56
EPHX2 P34913 1/20 0.54
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9357100 0.89 MEN1 (0.50) TSHRGAAKDM4EALDH1A1MEN1
SCHEMBL11195563 0.87 ALDH1A1 (0.50) TSHRCHRM2ADRA2ACYP2D6CHRM1
SCHEMBL11405129 0.86 TSHR (0.55) TSHRCHRM2HTR1AADRA2ACYP2D6
SCHEMBL6617503 0.85 BCHE (0.57) CHRM2HTR1AADRA2ACYP2D6CHRM1
SCHEMBL9353069 0.83 BCHE (0.56) CHRM2HTR1AADRA2ACYP2D6CHRM1
SCHEMBL14825908 0.83 TSHR (0.52) TSHRCHRM2CYP2D6GAAKDM4E
SCHEMBL9926016 0.83 SLC6A2 (0.64) TSHRCHRM2HTR1AADRA2ACYP2D6
Hydrochloric Acid SCHEMBL10436001 0.82 MAPK1 (0.56) CHRM2HTR1AADRA2ACYP2D6CHRM1
SCHEMBL14198379 0.82 TSHR (0.63) TSHRGAAMGLLKDM4EALDH1A1
SCHEMBL4254317 0.81 BCHE (0.59) CHRM2HTR1AADRA2ACYP2D6CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012076919-A1 PROCESS OF PREPARING EBASTINE MICRO LABS LIMITED (IN) 2012-06-14 WO disclosed
WO-2009157006-A1 PROCESS OF PREPARING EBASTINE MICRO LABS LIMITED (IN) 2009-12-30 WO disclosed
EP-1742707-A4 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS HYPNION INC (US) 2009-08-05 EP disclosed
US-7355042-B2 Treatment of CNS disorders using CNS target modulators HYPNION, INC. (US) 2008-04-08 US disclosed
US-7355042-B2 Treatment of CNS disorders using CNS target modulators HYPNION, INC. (US) 2008-04-08 US disclosed
US-7355042-B2 Treatment of CNS disorders using CNS target modulators HYPNION, INC. (US) 2008-04-08 US disclosed
EP-1443929-A4 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS HYPNION INC (US) 2008-02-06 EP disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US disclosed
US-7317026-B2 Sleep disorders; side effect reduction ; antihistamine antagonist HYPNION, INC. (US) 2008-01-08 US disclosed
US-20030187021-A1 Treatment of CNS disorders using CNS target modulators HYPNION, INC. 2003-10-02 US disclosed
WO-2003032912-A2 TREATMENT OF CNS DISORDERS USING CNS TARGET MODULATORS HYPNION, INC. (US) 2003-04-24 WO disclosed
US-6492364-B1 Triazolo and derivatives as chemokine inhibitors TORAY INDUSTRIES, INC. (JP) 2002-12-10 US disclosed
EP-1067130-A1 TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT TORAY INDUSTRIES, INC. (JP) 2001-01-10 EP disclosed
EP-0134124-B1 PIPERIDINE DERIVATIVES FORDONAL, S.A. (ES) 1987-10-28 EP disclosed
US-4550116-A ANTIALLERGENS, CARDIOVASCULAR AND RESPIRATORY DISORDERS FORDONAL, S.A. (ES) 1985-10-29 US disclosed
EP-0134124-A1 Piperidine derivatives FORDONAL, S.A. (ES) 1985-03-13 EP disclosed
US-4377578-A ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES JANSSEN PHARMACEUTICA, N.V. (BE) 1983-03-22 US disclosed
US-4250176-A BENZIMIDAZOLE-2-ONE, BENZOTHIAZOL-2-ONE, OR BENZOXAZOL-2-ONE SUBSTITUTIONS, ANTIANAPHALACTIC AGENTS, ANTIHISTAMINES JANSSEN PHARMACEUTICA N.V. (BE) 1981-02-10 US disclosed
US-4200641-A ANTIANAPHYLACTIC AGENTS, ANTIHISTAMINES JANSSEN PHARMACEUTICA, N.V. (BE) 1980-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187021-A1 Treatment of CNS disorders using CNS target modulators HCRTR2, CNR2, CNR1 TSHR 1566/4885CHRM2 68/4885HTR1A 138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.